MAGELLAN PHARMACY SOLUTIONS | MAGELLAN MEDICAID ADMINISTRATION

Kentucky UNBRIDLED SPIRIT

Pharmacy Quarterly

November 2012 Volume 8, Number 4

The Numbers Listed Below Are For Fee-For Service Support

Pharmacy Support Center

1-800-432-7005

24 hours per day/7 days per week
For claim assistance, early refill overrides, and lock-in overrides

Clinical Support Center

Prior Authorizations

1-800-477-3071

24 hours per day/7 days per week

Diabetic Supply Questions

Prior Authorization

1-800-477-3071

Claim Inquiry

1-800-432-7005

Please Note: Questions regarding claims prior to October 5, 2010, should be directed to 1-800-807-1232.

Provider Services

1-877-838-5085

M–F, 10:30 a.m.–4:30 p.m. (ET)

Providers should contact Provider Services for inquiries regarding enrollment and changes.

Member Services

1-800-635-2570

M–F, 8:00 a.m.–5:00 p.m. (ET)

Recipients should contact Member Services for medication replacement requests and benefit information.

Web Sites

Kentucky Department for Medicaid Services
http://chfs.ky.gov/dms/Pharmacy.htm

Magellan Medicaid Administration
https://kentucky.magellanmedicaid.com/

Onsite Provider Education

For onsite education presentations, please contact Kasie Purvis at 1-314-387-4792, M–F 8:30 a.m.–5:00 p.m. This education is free of charge.

Getting to Know Kentucky Medicaid Providers

Carpenter Dent Drugs has been "The People's Choice Since 1875." Approximately 30 percent of their clientele are Medicaid members. They have one full time pharmacist and two part time pharmacists, as well as eleven additional employees. Carpenter Dent Drugs offers a variety of services ranging from hormone testing and replacement therapy/consultation, postpartum care, skin care, and medication compounding.

Please visit http://www.carpenterdentdrugs.com/ for additional information regarding the services that are offered.

If you would like to see your pharmacy highlighted, please contact Kasie Purvis at KLPurvis@magellanhealth.com.

Upcoming Changes

Discontinuation of Drug Coverage Effective January 1, 2013

On January 1, 2013, Kentucky Medicaid will no longer provide the following coverage:

- Benzodiazepines for Medicare Part D members.
- Barbiturates for Medicare Part D members. The remaining Medicaid population will be approved if one of the following diagnosis is present:
  - Epilepsy, cancer, or chronic mental health disorder

Preferred Drug List (PDL) Changes

Please be looking for upcoming provider communication(s) that outline the PDL changes as a result of the November 15, 2012 Pharmacy and Therapeutics Advisory Committee (PTAC) meeting.

Fun Pharmacy Facts

Ancient History

The symbol "Rx" is actually an altered form of the ancient symbol for the Roman god Jupiter, whose blessing was called upon for every prescription to make certain of its purity.

Penicillin

During World War II, Britain feared that the Germans would invade their country and take their supply of penicillin. As a pre-emptive step, researchers smeared pocket linings with the penicillin mold to transport to the United States (US).

Licensed Pharmacists

In 1806, Louisiana became the first state to require that a pharmacist be licensed.

Clinical NewsError! Bookmark not defined.

Immune-mediated Necrotizing Myopathy (IMNM)

Risk of immune-mediated necrotizing myopathy (IMNM), a rare autoimmune myopathy, has recently been added to the statin class. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of a statin, muscle biopsy showing necrotizing myopathy without significant inflammation, and improvement with immunosuppressive agents.

Safety Label Change

The fenofibrate class of drugs has a safety label change to include paradoxical decreases in high-density lipoprotein cholesterol (HDL-C) in patients taking fenofibrates. Myopathy, including rhabdomyolysis, has also been reported with concomitant fenofibrate use in colchicine.

Drug Recalls

Earlier in November, Ranbaxy Laboratories issued a voluntary retail pharmacy level recall for 41 lots of generic version of Lipitor®, atorvastatin, with knowledge of the US Food and Drug Administration (FDA). The voluntary recall, of certain lots of 90 and 500 count bottles of atorvastatin, in dosage strengths of 10, 20, and 40 mg, was prompted out of concern that select batches may contain small glass particles, less than 1 mm in size. Atorvastatin 80 mg strengths were not recalled. On November 29, 2012, the FDA issued a statement on the Ranbaxy atorvastatin recall. The FDA announced that due to this quality issue, Ranbaxy will halt manufacturing of generic atorvastatin until it has thoroughly investigated the cause of the glass particles and fixed the problem. Although the 80 mg strength was not impacted by the recall, Ranbaxy has ceased production of all strengths of atorvastatin, including the 80 mg strength. There have not been any reports of injuries or deaths. The FDA is advising patients who may have received a recalled product to contact their pharmacists to confirm whether they received a recalled product, stop taking the product if it was recalled, and consult with their pharmacist or physician about how to obtain an alternative product. A complete list of affected atorvastatin lots is available at http://www.ranbaxyusa.com/. The FDA does not anticipate a shortage of atorvastatin, but is proactively monitoring the situation for the possibility of a shortage. The FDA is working with other manufacturers to ensure adequate market supply to avert a possible atorvastatin shortage. There are six generic manufacturers of Lipitor. Watson Pharmaceuticals makes the authorized generic. Pfizer continues to manufacture brand Lipitor. As of October 2012, Ranbaxy's generic atorvastatin covered approximately 44 percent of the US market for the drug (including brand and generic product). In recent years, Ranbaxy has been under scrutiny by the FDA and the US Department of Justice for alleged quality issues and falsification of data used to gain approval to market medications in the United States. Ranbaxy is currently operating under a consent decree, signed in December 2011.

Boehringer Ingelheim has recalled a single lot of dabigatran (Pradaxa®) 75 mg capsules. The recall is due to a potential packaging defect that may compromise the bottle integrity. This could allow moisture to enter the bottle and impair drug quality. Patients may not receive a fully effective dose, leading to an increased risk of an ischemic stroke.

Review of Bleeding Risks

The FDA has evaluated new information about the risk of serious bleeding associated with use of the anticoagulants dabigatran (Pradaxa) and warfarin. After the approval of dabigatran, the FDA received a large number of post-marketing reports of bleeding among dabigatran users. Prompted by these results, the FDA investigated the actual rates of gastrointestinal bleeding and intracranial hemorrhage for new users of dabigatran versus new users of warfarin. This assessment was done using insurance claims and administrative data from the FDA's Mini-Sentinel pilot of the Sentinel Initiative. The Sentinel Initiative was created to provide a system for active surveillance using pre-existing electronic health care data from multiple sources, as a means of assessing the safety of approved drugs and other medical products. The results of the Mini-Sentinel assessment regarding the safety of Pradaxa indicate that bleeding rates associated with the new use of Pradaxa do not appear to be higher than bleeding rates associated with the new use of warfarin. This is consistent with observations from the large clinical trial, which led to the approval of dabigatran, the RE-LY trial. The FDA has not changed its recommendations regarding dabigatran. The FDA continues to evaluate multiple sources of data in the ongoing safety review of this issue.

Drug Availability

There is currently a shortage of Abbott Laboratories' brand fenofibrate (Tricor®) 48mg tablets. They are not expected to be available for wholesaler inventory until February 2013. Abbott now has inventory of Tricor® 145mg tablets and is fulfilling wholesaler backorders.

[1] Magellan Medicaid Administration, Inc. Clinical Alert. December 2012. Available at: www.MagellanMedicaid.com/news/ClinicalAlerts.asp.